nodes	percent_of_prediction	percent_of_DWPC	metapath
Levobupivacaine—CYP1A2—Carmustine—lymphatic system cancer	0.254	0.471	CbGbCtD
Levobupivacaine—CYP3A4—Cytarabine—lymphatic system cancer	0.0906	0.168	CbGbCtD
Levobupivacaine—CYP3A4—Teniposide—lymphatic system cancer	0.0893	0.166	CbGbCtD
Levobupivacaine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0624	0.116	CbGbCtD
Levobupivacaine—CYP3A4—Vincristine—lymphatic system cancer	0.043	0.0798	CbGbCtD
Levobupivacaine—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00121	0.00262	CcSEcCtD
Levobupivacaine—Fungal infection—Methotrexate—lymphatic system cancer	0.00119	0.00258	CcSEcCtD
Levobupivacaine—Cough—Fludarabine—lymphatic system cancer	0.00118	0.00257	CcSEcCtD
Levobupivacaine—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00118	0.00256	CcSEcCtD
Levobupivacaine—Hypotension—Teniposide—lymphatic system cancer	0.00118	0.00255	CcSEcCtD
Levobupivacaine—Convulsion—Fludarabine—lymphatic system cancer	0.00118	0.00255	CcSEcCtD
Levobupivacaine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00117	0.00253	CcSEcCtD
Levobupivacaine—Arthralgia—Fludarabine—lymphatic system cancer	0.00115	0.0025	CcSEcCtD
Levobupivacaine—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00114	0.00246	CcSEcCtD
Levobupivacaine—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00113	0.00245	CcSEcCtD
Levobupivacaine—Dyspnoea—Teniposide—lymphatic system cancer	0.00112	0.00243	CcSEcCtD
Levobupivacaine—Confusional state—Fludarabine—lymphatic system cancer	0.00112	0.00242	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00111	0.0024	CcSEcCtD
Levobupivacaine—Oedema—Fludarabine—lymphatic system cancer	0.00111	0.0024	CcSEcCtD
Levobupivacaine—Infection—Fludarabine—lymphatic system cancer	0.0011	0.00238	CcSEcCtD
Levobupivacaine—Decreased appetite—Teniposide—lymphatic system cancer	0.00109	0.00237	CcSEcCtD
Levobupivacaine—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00109	0.00236	CcSEcCtD
Levobupivacaine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00109	0.00236	CcSEcCtD
Levobupivacaine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00109	0.00235	CcSEcCtD
Levobupivacaine—Apnoea—Methotrexate—lymphatic system cancer	0.00109	0.00235	CcSEcCtD
Levobupivacaine—Urinary tract infection—Carmustine—lymphatic system cancer	0.00108	0.00234	CcSEcCtD
Levobupivacaine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00107	0.00232	CcSEcCtD
Levobupivacaine—Flushing—Bleomycin—lymphatic system cancer	0.00106	0.0023	CcSEcCtD
Levobupivacaine—Extravasation—Methotrexate—lymphatic system cancer	0.00105	0.00229	CcSEcCtD
Levobupivacaine—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00104	0.00225	CcSEcCtD
Levobupivacaine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00104	0.00225	CcSEcCtD
Levobupivacaine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00103	0.00224	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00103	0.00223	CcSEcCtD
Levobupivacaine—Musculoskeletal stiffness—Methotrexate—lymphatic system cancer	0.00103	0.00222	CcSEcCtD
Levobupivacaine—Chills—Bleomycin—lymphatic system cancer	0.00103	0.00222	CcSEcCtD
Levobupivacaine—Bone disorder—Methotrexate—lymphatic system cancer	0.00102	0.00221	CcSEcCtD
Levobupivacaine—Skin discolouration—Methotrexate—lymphatic system cancer	0.00102	0.00221	CcSEcCtD
Levobupivacaine—Sweating—Vincristine—lymphatic system cancer	0.00102	0.0022	CcSEcCtD
Levobupivacaine—Nausea—Mechlorethamine—lymphatic system cancer	0.00101	0.0022	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00101	0.00219	CcSEcCtD
Levobupivacaine—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.001	0.00218	CcSEcCtD
Levobupivacaine—Urticaria—Teniposide—lymphatic system cancer	0.001	0.00217	CcSEcCtD
Levobupivacaine—Abdominal pain—Teniposide—lymphatic system cancer	0.000996	0.00216	CcSEcCtD
Levobupivacaine—Body temperature increased—Teniposide—lymphatic system cancer	0.000996	0.00216	CcSEcCtD
Levobupivacaine—Erythema—Bleomycin—lymphatic system cancer	0.000994	0.00216	CcSEcCtD
Levobupivacaine—Paraesthesia—Fludarabine—lymphatic system cancer	0.000994	0.00216	CcSEcCtD
Levobupivacaine—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000992	0.00215	CcSEcCtD
Levobupivacaine—Sweating—Mitoxantrone—lymphatic system cancer	0.00099	0.00215	CcSEcCtD
Levobupivacaine—Dyspnoea—Fludarabine—lymphatic system cancer	0.000987	0.00214	CcSEcCtD
Levobupivacaine—Haematuria—Mitoxantrone—lymphatic system cancer	0.000985	0.00213	CcSEcCtD
Levobupivacaine—Oedema peripheral—Carmustine—lymphatic system cancer	0.000982	0.00213	CcSEcCtD
Levobupivacaine—Dyspepsia—Fludarabine—lymphatic system cancer	0.000974	0.00211	CcSEcCtD
Levobupivacaine—Dysarthria—Methotrexate—lymphatic system cancer	0.000972	0.00211	CcSEcCtD
Levobupivacaine—Decreased appetite—Fludarabine—lymphatic system cancer	0.000962	0.00209	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000956	0.00207	CcSEcCtD
Levobupivacaine—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000947	0.00205	CcSEcCtD
Levobupivacaine—Pain—Fludarabine—lymphatic system cancer	0.000947	0.00205	CcSEcCtD
Levobupivacaine—Constipation—Fludarabine—lymphatic system cancer	0.000947	0.00205	CcSEcCtD
Levobupivacaine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000944	0.00205	CcSEcCtD
Levobupivacaine—Respiratory failure—Methotrexate—lymphatic system cancer	0.000937	0.00203	CcSEcCtD
Levobupivacaine—Hypersensitivity—Teniposide—lymphatic system cancer	0.000928	0.00201	CcSEcCtD
Levobupivacaine—Flushing—Carmustine—lymphatic system cancer	0.000925	0.00201	CcSEcCtD
Levobupivacaine—Anaemia—Bleomycin—lymphatic system cancer	0.000919	0.00199	CcSEcCtD
Levobupivacaine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000912	0.00198	CcSEcCtD
Levobupivacaine—Asthenia—Teniposide—lymphatic system cancer	0.000904	0.00196	CcSEcCtD
Levobupivacaine—Pruritus—Teniposide—lymphatic system cancer	0.000891	0.00193	CcSEcCtD
Levobupivacaine—Arrhythmia—Carmustine—lymphatic system cancer	0.000891	0.00193	CcSEcCtD
Levobupivacaine—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.000888	0.00193	CcSEcCtD
Levobupivacaine—Cardiac disorder—Vincristine—lymphatic system cancer	0.000883	0.00192	CcSEcCtD
Levobupivacaine—Body temperature increased—Fludarabine—lymphatic system cancer	0.000875	0.0019	CcSEcCtD
Levobupivacaine—Mental disorder—Carmustine—lymphatic system cancer	0.000874	0.00189	CcSEcCtD
Levobupivacaine—Erythema—Carmustine—lymphatic system cancer	0.000868	0.00188	CcSEcCtD
Levobupivacaine—Malnutrition—Carmustine—lymphatic system cancer	0.000868	0.00188	CcSEcCtD
Levobupivacaine—Cough—Bleomycin—lymphatic system cancer	0.000868	0.00188	CcSEcCtD
Levobupivacaine—Diarrhoea—Teniposide—lymphatic system cancer	0.000862	0.00187	CcSEcCtD
Levobupivacaine—Back pain—Carmustine—lymphatic system cancer	0.00084	0.00182	CcSEcCtD
Levobupivacaine—Mental disorder—Vincristine—lymphatic system cancer	0.000834	0.00181	CcSEcCtD
Levobupivacaine—Chills—Mitoxantrone—lymphatic system cancer	0.000832	0.0018	CcSEcCtD
Levobupivacaine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000828	0.0018	CcSEcCtD
Levobupivacaine—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000819	0.00178	CcSEcCtD
Levobupivacaine—Confusional state—Bleomycin—lymphatic system cancer	0.000818	0.00177	CcSEcCtD
Levobupivacaine—Vision blurred—Carmustine—lymphatic system cancer	0.000818	0.00177	CcSEcCtD
Levobupivacaine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000816	0.00177	CcSEcCtD
Levobupivacaine—Tremor—Carmustine—lymphatic system cancer	0.000813	0.00176	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000812	0.00176	CcSEcCtD
Levobupivacaine—Oedema—Bleomycin—lymphatic system cancer	0.000812	0.00176	CcSEcCtD
Levobupivacaine—Erythema—Mitoxantrone—lymphatic system cancer	0.000807	0.00175	CcSEcCtD
Levobupivacaine—Infection—Bleomycin—lymphatic system cancer	0.000806	0.00175	CcSEcCtD
Levobupivacaine—Anaemia—Carmustine—lymphatic system cancer	0.000802	0.00174	CcSEcCtD
Levobupivacaine—Back pain—Vincristine—lymphatic system cancer	0.000802	0.00174	CcSEcCtD
Levobupivacaine—Vomiting—Teniposide—lymphatic system cancer	0.000801	0.00174	CcSEcCtD
Levobupivacaine—Agitation—Carmustine—lymphatic system cancer	0.000798	0.00173	CcSEcCtD
Levobupivacaine—Asthenia—Fludarabine—lymphatic system cancer	0.000794	0.00172	CcSEcCtD
Levobupivacaine—Headache—Teniposide—lymphatic system cancer	0.000789	0.00171	CcSEcCtD
Levobupivacaine—Pruritus—Fludarabine—lymphatic system cancer	0.000783	0.0017	CcSEcCtD
Levobupivacaine—Back pain—Mitoxantrone—lymphatic system cancer	0.000781	0.00169	CcSEcCtD
Levobupivacaine—Anaemia—Vincristine—lymphatic system cancer	0.000766	0.00166	CcSEcCtD
Levobupivacaine—Agitation—Vincristine—lymphatic system cancer	0.000761	0.00165	CcSEcCtD
Levobupivacaine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000761	0.00165	CcSEcCtD
Levobupivacaine—Hypotension—Bleomycin—lymphatic system cancer	0.000758	0.00164	CcSEcCtD
Levobupivacaine—Diarrhoea—Fludarabine—lymphatic system cancer	0.000757	0.00164	CcSEcCtD
Levobupivacaine—Convulsion—Carmustine—lymphatic system cancer	0.000752	0.00163	CcSEcCtD
Levobupivacaine—Hypertension—Carmustine—lymphatic system cancer	0.000749	0.00163	CcSEcCtD
Levobupivacaine—Nausea—Teniposide—lymphatic system cancer	0.000748	0.00162	CcSEcCtD
Levobupivacaine—Anaemia—Mitoxantrone—lymphatic system cancer	0.000746	0.00162	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000739	0.0016	CcSEcCtD
Levobupivacaine—Anxiety—Carmustine—lymphatic system cancer	0.000736	0.0016	CcSEcCtD
Levobupivacaine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000729	0.00158	CcSEcCtD
Levobupivacaine—Dyspnoea—Bleomycin—lymphatic system cancer	0.000724	0.00157	CcSEcCtD
Levobupivacaine—Convulsion—Vincristine—lymphatic system cancer	0.000718	0.00156	CcSEcCtD
Levobupivacaine—Hypertension—Vincristine—lymphatic system cancer	0.000715	0.00155	CcSEcCtD
Levobupivacaine—Confusional state—Carmustine—lymphatic system cancer	0.000714	0.00155	CcSEcCtD
Levobupivacaine—Oedema—Carmustine—lymphatic system cancer	0.000708	0.00154	CcSEcCtD
Levobupivacaine—Decreased appetite—Bleomycin—lymphatic system cancer	0.000706	0.00153	CcSEcCtD
Levobupivacaine—Cough—Mitoxantrone—lymphatic system cancer	0.000704	0.00153	CcSEcCtD
Levobupivacaine—Infection—Carmustine—lymphatic system cancer	0.000704	0.00153	CcSEcCtD
Levobupivacaine—Vomiting—Fludarabine—lymphatic system cancer	0.000704	0.00153	CcSEcCtD
Levobupivacaine—Convulsion—Mitoxantrone—lymphatic system cancer	0.000699	0.00152	CcSEcCtD
Levobupivacaine—Hypertension—Mitoxantrone—lymphatic system cancer	0.000697	0.00151	CcSEcCtD
Levobupivacaine—Pain—Bleomycin—lymphatic system cancer	0.000694	0.0015	CcSEcCtD
Levobupivacaine—Headache—Fludarabine—lymphatic system cancer	0.000693	0.0015	CcSEcCtD
Levobupivacaine—Tachycardia—Carmustine—lymphatic system cancer	0.000691	0.0015	CcSEcCtD
Levobupivacaine—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00069	0.0015	CcSEcCtD
Levobupivacaine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000687	0.00149	CcSEcCtD
Levobupivacaine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000685	0.00148	CcSEcCtD
Levobupivacaine—Lethargy—Methotrexate—lymphatic system cancer	0.000681	0.00148	CcSEcCtD
Levobupivacaine—Oedema—Vincristine—lymphatic system cancer	0.000676	0.00147	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000676	0.00147	CcSEcCtD
Levobupivacaine—Infection—Vincristine—lymphatic system cancer	0.000672	0.00146	CcSEcCtD
Levobupivacaine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000669	0.00145	CcSEcCtD
Levobupivacaine—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000668	0.00145	CcSEcCtD
Levobupivacaine—Confusional state—Mitoxantrone—lymphatic system cancer	0.000664	0.00144	CcSEcCtD
Levobupivacaine—Nervous system disorder—Vincristine—lymphatic system cancer	0.000663	0.00144	CcSEcCtD
Levobupivacaine—Hypotension—Carmustine—lymphatic system cancer	0.000662	0.00144	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000659	0.00143	CcSEcCtD
Levobupivacaine—Oedema—Mitoxantrone—lymphatic system cancer	0.000659	0.00143	CcSEcCtD
Levobupivacaine—Nausea—Fludarabine—lymphatic system cancer	0.000658	0.00143	CcSEcCtD
Levobupivacaine—Infection—Mitoxantrone—lymphatic system cancer	0.000654	0.00142	CcSEcCtD
Levobupivacaine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000654	0.00142	CcSEcCtD
Levobupivacaine—Shock—Mitoxantrone—lymphatic system cancer	0.000648	0.00141	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000645	0.0014	CcSEcCtD
Levobupivacaine—Urticaria—Bleomycin—lymphatic system cancer	0.000645	0.0014	CcSEcCtD
Levobupivacaine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000643	0.00139	CcSEcCtD
Levobupivacaine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000642	0.00139	CcSEcCtD
Levobupivacaine—Insomnia—Carmustine—lymphatic system cancer	0.000641	0.00139	CcSEcCtD
Levobupivacaine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00064	0.00139	CcSEcCtD
Levobupivacaine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000637	0.00138	CcSEcCtD
Levobupivacaine—Paraesthesia—Carmustine—lymphatic system cancer	0.000636	0.00138	CcSEcCtD
Levobupivacaine—Hypotension—Vincristine—lymphatic system cancer	0.000632	0.00137	CcSEcCtD
Levobupivacaine—Dyspnoea—Carmustine—lymphatic system cancer	0.000632	0.00137	CcSEcCtD
Levobupivacaine—Somnolence—Carmustine—lymphatic system cancer	0.00063	0.00137	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000616	0.00134	CcSEcCtD
Levobupivacaine—Decreased appetite—Carmustine—lymphatic system cancer	0.000616	0.00134	CcSEcCtD
Levobupivacaine—Hypotension—Mitoxantrone—lymphatic system cancer	0.000615	0.00133	CcSEcCtD
Levobupivacaine—Insomnia—Vincristine—lymphatic system cancer	0.000612	0.00133	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000612	0.00133	CcSEcCtD
Levobupivacaine—Paraesthesia—Vincristine—lymphatic system cancer	0.000607	0.00132	CcSEcCtD
Levobupivacaine—Constipation—Carmustine—lymphatic system cancer	0.000606	0.00131	CcSEcCtD
Levobupivacaine—Pain—Carmustine—lymphatic system cancer	0.000606	0.00131	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.0006	0.0013	CcSEcCtD
Levobupivacaine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000598	0.0013	CcSEcCtD
Levobupivacaine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000591	0.00128	CcSEcCtD
Levobupivacaine—Decreased appetite—Vincristine—lymphatic system cancer	0.000588	0.00127	CcSEcCtD
Levobupivacaine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000587	0.00127	CcSEcCtD
Levobupivacaine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000586	0.00127	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000584	0.00127	CcSEcCtD
Levobupivacaine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000584	0.00127	CcSEcCtD
Levobupivacaine—Asthenia—Bleomycin—lymphatic system cancer	0.000582	0.00126	CcSEcCtD
Levobupivacaine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00058	0.00126	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000579	0.00126	CcSEcCtD
Levobupivacaine—Pain—Vincristine—lymphatic system cancer	0.000578	0.00125	CcSEcCtD
Levobupivacaine—Constipation—Vincristine—lymphatic system cancer	0.000578	0.00125	CcSEcCtD
Levobupivacaine—Pruritus—Bleomycin—lymphatic system cancer	0.000574	0.00125	CcSEcCtD
Levobupivacaine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000573	0.00124	CcSEcCtD
Levobupivacaine—Pain—Mitoxantrone—lymphatic system cancer	0.000563	0.00122	CcSEcCtD
Levobupivacaine—Constipation—Mitoxantrone—lymphatic system cancer	0.000563	0.00122	CcSEcCtD
Levobupivacaine—Abdominal pain—Carmustine—lymphatic system cancer	0.00056	0.00121	CcSEcCtD
Levobupivacaine—Body temperature increased—Carmustine—lymphatic system cancer	0.00056	0.00121	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000553	0.0012	CcSEcCtD
Levobupivacaine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000543	0.00118	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000539	0.00117	CcSEcCtD
Levobupivacaine—Abdominal pain—Vincristine—lymphatic system cancer	0.000535	0.00116	CcSEcCtD
Levobupivacaine—Body temperature increased—Vincristine—lymphatic system cancer	0.000535	0.00116	CcSEcCtD
Levobupivacaine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000523	0.00113	CcSEcCtD
Levobupivacaine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000522	0.00113	CcSEcCtD
Levobupivacaine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000521	0.00113	CcSEcCtD
Levobupivacaine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000521	0.00113	CcSEcCtD
Levobupivacaine—Vomiting—Bleomycin—lymphatic system cancer	0.000516	0.00112	CcSEcCtD
Levobupivacaine—Drowsiness—Methotrexate—lymphatic system cancer	0.000515	0.00112	CcSEcCtD
Levobupivacaine—Infestation—Methotrexate—lymphatic system cancer	0.000515	0.00112	CcSEcCtD
Levobupivacaine—Infestation NOS—Methotrexate—lymphatic system cancer	0.000515	0.00112	CcSEcCtD
Levobupivacaine—Asthenia—Carmustine—lymphatic system cancer	0.000508	0.0011	CcSEcCtD
Levobupivacaine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000498	0.00108	CcSEcCtD
Levobupivacaine—Sweating—Methotrexate—lymphatic system cancer	0.000493	0.00107	CcSEcCtD
Levobupivacaine—Haematuria—Methotrexate—lymphatic system cancer	0.000491	0.00106	CcSEcCtD
Levobupivacaine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000485	0.00105	CcSEcCtD
Levobupivacaine—Asthenia—Vincristine—lymphatic system cancer	0.000485	0.00105	CcSEcCtD
Levobupivacaine—Diarrhoea—Carmustine—lymphatic system cancer	0.000485	0.00105	CcSEcCtD
Levobupivacaine—Nausea—Bleomycin—lymphatic system cancer	0.000482	0.00105	CcSEcCtD
Levobupivacaine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000473	0.00102	CcSEcCtD
Levobupivacaine—Dizziness—Carmustine—lymphatic system cancer	0.000468	0.00102	CcSEcCtD
Levobupivacaine—Diarrhoea—Vincristine—lymphatic system cancer	0.000463	0.001	CcSEcCtD
Levobupivacaine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000451	0.000977	CcSEcCtD
Levobupivacaine—Vomiting—Carmustine—lymphatic system cancer	0.00045	0.000977	CcSEcCtD
Levobupivacaine—Dizziness—Vincristine—lymphatic system cancer	0.000447	0.00097	CcSEcCtD
Levobupivacaine—Headache—Carmustine—lymphatic system cancer	0.000444	0.000962	CcSEcCtD
Levobupivacaine—Tinnitus—Methotrexate—lymphatic system cancer	0.000431	0.000934	CcSEcCtD
Levobupivacaine—Vomiting—Vincristine—lymphatic system cancer	0.00043	0.000932	CcSEcCtD
Levobupivacaine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000429	0.000929	CcSEcCtD
Levobupivacaine—Headache—Vincristine—lymphatic system cancer	0.000424	0.000919	CcSEcCtD
Levobupivacaine—Nausea—Carmustine—lymphatic system cancer	0.000421	0.000912	CcSEcCtD
Levobupivacaine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000419	0.000908	CcSEcCtD
Levobupivacaine—Chills—Methotrexate—lymphatic system cancer	0.000414	0.000899	CcSEcCtD
Levobupivacaine—Headache—Mitoxantrone—lymphatic system cancer	0.000413	0.000895	CcSEcCtD
Levobupivacaine—Mental disorder—Methotrexate—lymphatic system cancer	0.000405	0.000877	CcSEcCtD
Levobupivacaine—Malnutrition—Methotrexate—lymphatic system cancer	0.000402	0.000872	CcSEcCtD
Levobupivacaine—Erythema—Methotrexate—lymphatic system cancer	0.000402	0.000872	CcSEcCtD
Levobupivacaine—Nausea—Vincristine—lymphatic system cancer	0.000402	0.000871	CcSEcCtD
Levobupivacaine—Nausea—Mitoxantrone—lymphatic system cancer	0.000391	0.000848	CcSEcCtD
Levobupivacaine—Back pain—Methotrexate—lymphatic system cancer	0.000389	0.000843	CcSEcCtD
Levobupivacaine—Vision blurred—Methotrexate—lymphatic system cancer	0.000379	0.000822	CcSEcCtD
Levobupivacaine—Anaemia—Methotrexate—lymphatic system cancer	0.000372	0.000806	CcSEcCtD
Levobupivacaine—Cough—Methotrexate—lymphatic system cancer	0.000351	0.000761	CcSEcCtD
Levobupivacaine—Convulsion—Methotrexate—lymphatic system cancer	0.000348	0.000755	CcSEcCtD
Levobupivacaine—Arthralgia—Methotrexate—lymphatic system cancer	0.000342	0.000742	CcSEcCtD
Levobupivacaine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00034	0.000737	CcSEcCtD
Levobupivacaine—Confusional state—Methotrexate—lymphatic system cancer	0.000331	0.000717	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000328	0.000712	CcSEcCtD
Levobupivacaine—Infection—Methotrexate—lymphatic system cancer	0.000326	0.000707	CcSEcCtD
Levobupivacaine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000322	0.000698	CcSEcCtD
Levobupivacaine—Skin disorder—Methotrexate—lymphatic system cancer	0.000319	0.000691	CcSEcCtD
Levobupivacaine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000317	0.000688	CcSEcCtD
Levobupivacaine—Hypotension—Methotrexate—lymphatic system cancer	0.000307	0.000665	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000299	0.000648	CcSEcCtD
Levobupivacaine—Insomnia—Methotrexate—lymphatic system cancer	0.000297	0.000644	CcSEcCtD
Levobupivacaine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000295	0.000639	CcSEcCtD
Levobupivacaine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000293	0.000634	CcSEcCtD
Levobupivacaine—Somnolence—Methotrexate—lymphatic system cancer	0.000292	0.000633	CcSEcCtD
Levobupivacaine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000289	0.000626	CcSEcCtD
Levobupivacaine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000285	0.000619	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000283	0.000614	CcSEcCtD
Levobupivacaine—Pain—Methotrexate—lymphatic system cancer	0.000281	0.000608	CcSEcCtD
Levobupivacaine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00027	0.000586	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000268	0.000582	CcSEcCtD
Levobupivacaine—Urticaria—Methotrexate—lymphatic system cancer	0.000261	0.000565	CcSEcCtD
Levobupivacaine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000259	0.000562	CcSEcCtD
Levobupivacaine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000259	0.000562	CcSEcCtD
Levobupivacaine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000242	0.000524	CcSEcCtD
Levobupivacaine—Asthenia—Methotrexate—lymphatic system cancer	0.000235	0.000511	CcSEcCtD
Levobupivacaine—Pruritus—Methotrexate—lymphatic system cancer	0.000232	0.000503	CcSEcCtD
Levobupivacaine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000225	0.000487	CcSEcCtD
Levobupivacaine—Dizziness—Methotrexate—lymphatic system cancer	0.000217	0.000471	CcSEcCtD
Levobupivacaine—Vomiting—Methotrexate—lymphatic system cancer	0.000209	0.000452	CcSEcCtD
Levobupivacaine—Headache—Methotrexate—lymphatic system cancer	0.000206	0.000446	CcSEcCtD
Levobupivacaine—Nausea—Methotrexate—lymphatic system cancer	0.000195	0.000423	CcSEcCtD
